Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04997902 · ClinicalTrials.gov registry record · Phase 1
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
A Phase 1 study, sponsored by Kura Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT04997902 is a Phase 1 study that has completed, run by Kura Oncology. The registered enrollment target is 45 participants.
The verdict
NCT04997902, a Phase 1 study, has completed, sponsored by Kura Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress the HRAS protein and/or are PIK3CA-mutated and/or PIK3CA-amplified.
Interventions
- DRUG Tipifarnib
- DRUG Alpelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-12-07 |
| Est. Completion | 2025-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04997902
The ClinicalTrials.gov registry entry for NCT04997902 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kura Oncology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tipifarnib is the first listed.
NCT04997902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04997902 about?
NCT04997902 is a clinical study titled "Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)". This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress the HRAS protein and/or are PIK3CA-mutated and/or PIK3CA-amplified.
What is the current status of trial NCT04997902?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2021-12-07. Estimated completion is 2025-08-29.
What interventions are being tested in trial NCT04997902?
The interventions under investigation include: Tipifarnib (DRUG), Alpelisib (DRUG).
Who is sponsoring clinical trial NCT04997902?
This trial is sponsored by Kura Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.